// App-Quantinova.ai

1069 ⋆ : Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1‐4 HCV‐Infected Liver Transplant Recipients

Researchers

Presenter

  • Kosh Agarwal

Principal Investigators

  • Lluis Castells

  • Beat Mullhaupt

  • William M. Rosenberg

  • Brian L. McNabb

  • Sarah Arterburn

  • Gregory Camus

  • John McNally

  • Diana M. Brainard

  • Mani Subramanian

  • Enoka Gonsalkorala

  • Maria Londoho

  • Jean-Franois Dufour

  • Xavier Forns

Medical Centers

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Hospital Universitario del Mar, Barcelona, Spain

  • Institute of Neurology, University College London, London, United Kingdom

  • Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA

  • Biostatistics, Gilead Sciences, Inc, Foster City, CA

  • Gilead Sciences, Inc., Foster City, CA

  • Hospital Clinic de Barcelona/IDIBAPS/IJC, Barcelona, Spain

  • University of Bern, Bern, Switzerland

Locations

  • United Kingdom

  • Spain

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • Velpatasvir/sofosbuvir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved